Revance Therapeutics, Inc. is a US-based pharmaceutical company with a focus on aesthetic and therapeutic offerings in the biotechnology industry. The company's ESG score is 27.7, putting it at a medium risk level. Revance has a range of products, including the DaxibotulinumtoxinA for Injection and the RHA Collection of dermal fillers. The company operates in two main segments: Products and Services, with the Products segment driving the majority of its revenue. With a focus on sustainability and governance, Revance Therapeutics, Inc. is a leader in the pharmaceutical industry.